Extended Data Figure 6. Melanoma PD-L1 is associated with T cell exhaustion, response, and survival for patients treated on clinical trial of RT + anti-CTLA4.

a) Representative images (right) for patients with biopsies showing PD-L1 staining on tumor cells classified as PD-L1^lo (top), 2+ (middle), or 3+ (bottom). Scores of 2+ and 3+ are classified as PD-L1^hi. The arrow indicates PD-L1 staining on macrophages. An isotype antibody negative control and positive controls are shown (left). b) Changes in % Ki67⁺GzmB⁺ in PD-1⁺ CD8 T cells after RT + anti-CTLA4 vs. PD-L1 status on melanoma cells from all patients with available pre- and post-treatment blood. c) Changes in % Ki67⁺GzmB⁺ in PD1⁺Eomes⁺ CD8 T cells (left) or in PD1⁺ CD8 T cells (right) vs. macrophage PD-L1 status. d) Hazard ratio and 95% CI for PFS from a Cox regression model using PD-L1 status on tumor cells and macrophages. e) Model for non-redundant mechanisms and resistance to RT and immune checkpoint blockade.